Back

NOD2 activation reprograms infiltrating inflammatory monocytes in the Zika virus infected CNS to maintain neural correlates of learning and memory

Hill, J. D.; Dong, A. H. W.; Liu, J.; Barbezani, M. D.; Andrews, T. M.; Klein, R. S.

2026-05-21 immunology
10.64898/2026.05.19.726300 bioRxiv
Show abstract

Zika virus (ZIKV) encephalitis induces cytokine-mediated cognitive deficits which persist long-term. Here, we determined if NOD2-mediated conversion of monocytes from Ly6CHi inflammatory to Ly6CLo anti-inflammatory phenotypes during ZIKV encephalitis preserves neural correlates of learning and memory within the hippocampus. Short-term administration of the NOD2 agonist, muramyl dipeptide (MDP), during peak ZIKV infection prevents synapse elimination and loss of adult hippocampal neurogenesis, without impacting CNS virologic control. Transcriptomic analyses of forebrain immune cells in MDP-treated mice revealed functional modulation of infiltrated monocytes and T cells, reducing their expression of pro-inflammatory cytokines, with limited effects on microglia, compared to controls. Notably, NOD2 activation in peripheral immune cells alone balances innate immune signals, preserving synapses, and increasing macrophage phagocytic capacities that do not target synapses. Our findings identify infiltrating Ly6CHi monocytes as key drivers of long-term cognitive dysfunction following ZIKV encephalitis and as potential therapeutic targets for limiting synapse loss. HighlightsO_LINOD2 activation via MDP phenotypically shifts monocyte subsets from inflammatory to anti-inflammatory during the acute phase of ZIKV encephalitis. C_LIO_LIShort-term MDP administration increases phagocytic machinery and reduces inflammatory cytokine/chemokine production within macrophage populations. C_LIO_LISynapse elimination is attenuated within the hippocampus of ZIKV-infected animals treated with MDP. C_LIO_LIMDP derived effects are mediated through peripherally derived immune cells. C_LI

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Immunity
58 papers in training set
Top 0.1%
22.2%
2
Nature Communications
4913 papers in training set
Top 23%
8.3%
3
Cell Reports
1338 papers in training set
Top 4%
8.3%
4
Journal of Experimental Medicine
106 papers in training set
Top 0.6%
4.3%
5
PLOS Pathogens
721 papers in training set
Top 3%
3.9%
6
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 19%
3.8%
50% of probability mass above
7
Science Immunology
81 papers in training set
Top 0.5%
3.8%
8
Journal of Neuroinflammation
50 papers in training set
Top 0.2%
3.5%
9
Brain, Behavior, and Immunity
105 papers in training set
Top 0.7%
3.5%
10
Nature Immunology
71 papers in training set
Top 0.8%
3.0%
11
Science Translational Medicine
111 papers in training set
Top 1%
3.0%
12
PLOS Biology
408 papers in training set
Top 7%
2.0%
13
eLife
5422 papers in training set
Top 36%
2.0%
14
Cell Reports Medicine
140 papers in training set
Top 4%
1.7%
15
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.7%
16
Frontiers in Immunology
586 papers in training set
Top 4%
1.6%
17
Cell
370 papers in training set
Top 12%
1.6%
18
Journal of Clinical Investigation
164 papers in training set
Top 4%
1.5%
19
Science
429 papers in training set
Top 16%
1.3%
20
JCI Insight
241 papers in training set
Top 5%
1.3%
21
Science Advances
1098 papers in training set
Top 24%
1.2%
22
mBio
750 papers in training set
Top 9%
1.1%
23
The EMBO Journal
267 papers in training set
Top 4%
0.9%
24
Nature
575 papers in training set
Top 16%
0.7%
25
The Lancet Infectious Diseases
71 papers in training set
Top 3%
0.7%
26
iScience
1063 papers in training set
Top 35%
0.7%
27
Acta Neuropathologica
51 papers in training set
Top 1%
0.6%
28
The Journal of Immunology
146 papers in training set
Top 2%
0.6%